The certificate says 2025. The vial in your hand does not say anything.
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
Delphine Ruzek
Page 5 of 7 of this archive, newest first.
Archive — page 5
121 piecesThe arithmetic of a step: what doubling a dose actually asks of you
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Everything a buyer assumes has been checked, ranked by whether it has
The absences are not concealment. They are the form the trade settled on, and no buyer has ever objected.
Hydration, protein and the two failures that compound each other
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
What we would need to measure to explain the response distribution
The mechanism is well described. The variance is not.
Reading a certificate for what it does not say
The most consequential features of most certificates in this market are the tests that do not appear on them at all.
The visceral fat result nobody quotes, from the substudy everybody cites
The trials measured mass. Nobody measured whether the participants got weaker.
Reflux, early satiety, and the volume the stomach will accept
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Choosing a needle for a subcutaneous peptide
Gauge affects pain and flow rate rather than depth. A finer needle is more comfortable and slower, and with a viscous solution the difference is noticeable.
Why no trial in this class has reported a strength endpoint
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Why a drug that acts on the pancreas changes what food tastes like
A tour of the tissues where the receptor is expressed, and what happens in each.
The reproducible spectrum: the single most useful thing a report can carry
What the Journal asks for when it writes to a supplier about an identity claim, and how often it gets it.
Delayed emptying explains some of this, and not all of it
What scintigraphy and breath-test studies established about emptying rate, and what they did not.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
The label says four weeks. The clinic says whatever holds.
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
Discontinuation rates, read honestly
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
Twelve minutes or forty: what gradient slope buys
A shallow gradient resolves impurities that a steep one runs into the parent peak. Both methods are legitimate; only one of them can see the small stuff.
Amylin is not an incretin, and cagrilintide is not a GLP-1 agonist
The glucagon arm raises energy expenditure and also raises hepatic glucose output. Balancing those is the whole engineering problem.
The substudies, read properly: who was scanned, when, and with what
Both the reassuring reading and the alarming reading are supportable from the same tables. This piece sets out which is which.
What orthogonal actually means, and what it does not
An orthogonal method separates on a different physical principle, so that species co-eluting in the first are likely to resolve in the second. Two runs of the same method at…